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70Secukinumab shows significant efficacy
in palmoplantar psoriasis: Results from
GESTURE, a randomized controlled trialAlice Gottlieb, MD, PhD,a John Sullivan, MD,b Martijn van Doorn, MD,c Alexey Kubanov, MD,d
Ruquan You, MSc,e Anne Parneix, MD,f Sophie Hugot, MSc,g and Marina Milutinovic, MDg
Valhalla, New York; Darlinghurst, Australia; Rotterdam, The Netherlands; Moscow, Russia; Shanghai,
China; East Hanover, New Jersey; and Basel, SwitzerlandBackground: Plaque psoriasis affecting palms and soles is disabling and often resistant to treatment.Objective: Evaluate the efficacy and safety of secukinumab, an anti-interleukin 17A antibody, in subjects
with palmoplantar psoriasis.Methods: In this double-blinded, randomized controlled trial, 205 subjects were randomized 1:1:1 to
secukinumab 300 mg, 150 mg, or placebo. The primary endpoint was Palmoplantar Investigator’s Global
Assessment (ppIGA) 0 (clear) or 1 (almost clear/minimal) response at week 16.Results: At week 16, the percentage of subjects who achieved clear or almost clear palms and soles (or
ppIGA 0/1) with secukinumab 300 mg (33.3%) and 150 mg (22.1%) was superior to the percentage
achieved with placebo (1.5%, P \ .001). Palmoplantar Psoriasis Area and Severity Index (ppPASI) was
significantly reduced with secukinumab 300 mg (54.5%) and 150 mg (35.3%) compared with placebo
(4.0%, P\.001). Dermatology Life Quality Index (DLQI) 0/1 responses from subjects in the secukinumab
groups were also significantly higher compared with placebo at week 16 (P\ .01) and pain and function
of palms and soles was markedly improved with secukinumab as measured by the palmoplantar
Quality-of-Life Instrument. Secukinumab 300 mg consistently showed the best outcomes. The safety profile
was favorable and similar to previous studies.Limitations: Lack of active comparator.Conclusion: In GESTURE, the largest randomized controlled trial in palmoplantar psoriasis, secukinumab
demonstrated the greatest efficacy to date for treating difficult-to-treat psoriasis. ( J Am Acad Dermatol
2017;76:70-80.)
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Gottlieb et al 71Palmoplantar psoriasis, plaque psoriasis on the
palms and soles, is present in up to 40% of plaque
psoriasis patients and is known to be difficult to
treat.1 Palms and soles are crucial for function and, as
a consequence, palmoplantar psoriasis leads to a
disproportionately greater impairment of health-
related quality of life (HRQoL) compared withCAPSULE SUMMARY
d Palmoplantar psoriasis is difficult-to-treat
and significantly impacts quality of life.
d At 16 weeks, one-third of subjects
treated with secukinumab 300 mg
showed clear or almost clear palms and
soles with a significant improvement in
quality of life.
d Secukinumab represents a new
therapeutic option for the treatment of
palmoplantar psoriasis.plaque psoriasis on other
parts of the body.2 Patients
suffer from a significant
amount of pain in the palms
and soles, have impaired
dexterity of the hands, diffi-
culty walking, and an
inability to work.2-4 Many
patients with palmoplantar
psoriasis do not have exten-
sive psoriasis on other body
parts, therefore the total
body surface area (BSA)
affected by psoriasis is often
lower than 10%, excluding
them from most psoriasis
clinical trials. Because of its profound impact on
quality of life, even greater than in moderate-to-
severe psoriasis,5 and regardless of there often being
a low BSA affected, the National Psoriasis
Foundation considers palmoplantar psoriasis to be
a severe form of psoriasis.6
Palmoplantar psoriasis is known as recalcitrant
due to it being difficult to treat. Biologics have shown
better efficacy than other treatment options7-9;
however, the efficacy achieved with biologics in
treating palmoplantar psoriasis is markedly lower
than that achieved by these agents in psoriasis on
other parts of the body.
Palmoplantar psoriasis has rarely been studied in
clinical trials, whichmay explainwhy there is no clear
treatment algorithm10 and has been recognized as
one of the top priorities in psoriasis research by the
International Psoriasis Council.11 The data that does
exist often comes from research with heterogeneous
patient populations or small sample sizes and/or
from a subgroup/post-hoc analysis from trials in
which palmoplantar psoriasis was not themain focus
of research.12-15 Therefore, a high unmet need for an
effective treatment, confirmed by large randomized
placebo-controlled studies specifically designed for
palmoplantar psoriasis patients, remains.
Interleukin (IL)-17A is a cytokine that plays a key
role in immune-mediated disorders including
psoriasis.16,17 Secukinumab is a fully human IgG1k
monoclonal antibody that selectively binds
and neutralizes IL-17A.18,19 Results from phase 3
clinical trials have demonstrated high efficacy ofsecukinumab in moderate-to-severe psoriasis, start-
ing at early time points, with a sustained effect and a
favorable safety profile.18-22 Secukinumab has also
shown superiority to etanercept20 and ustekinu-
mab23 in head-to-head trials. Post-hoc analysis of a
relatively small subgroup of palmoplantar psoriasis
subjects from a secukinumab phase 2 study inmoderate-to-severe psoriasis
showed promising initial
results.24
Thepresentphase3bstudy,
GESTURE, was designed to
evaluate theefficacyandsafety
of secukinumab specifically in
subjects with palmoplantar
psoriasis. Here we report re-
sults up to week 16, the time
point of the primary objective
assessment.
MATERIALS AND
METHODS
Study designGESTURE was a randomized, double-blind,
placebo-controlled, multicenter, phase 3b trial
conducted across 15 countries (Clinicaltrials.gov
NCT01806597). The first subject’s first visit was on
June 19, 2013, and the last subject’s last 16-week visit
occurred on July 2, 2014. The studywas conducted in
accordance with principles of the Declaration of
Helsinki.
Eligible subjects were randomized 1:1:1, via an
interactive response technology system, to secuki-
numab 300 mg, secukinumab 150 mg, or placebo
delivered subcutaneously. Randomization was
stratified at baseline by body weight (\90 kg or
$90 kg). An overview of the study design is
presented in Fig 1.
The primary endpoint was Palmoplantar
Investigator’s Global Assessment (ppIGA) 0 (clear)
or 1 (almost clear/minimal) response at week 16.
Investigators, subjects, and the sponsor study team
remained blinded to treatment assignment until the
end of study.
Subjects
Eligible subjects were $18 years old with
moderate-to-severe palmoplantar psoriasis (ppIGA
score of $3 [on a 5-point scale]) and at least one
additional plaque outside of the palms and soles to
confirm the diagnosis of plaque psoriasis.
Subjects must have had disease previously
inadequately controlled by topicals, phototherapy,
and/or systemic therapy. Subjects with forms of
psoriasis other than plaque (such as palmoplantar
Abbreviations used:
AE: adverse event
BSA: body surface area
DLQI: Dermatology Life Quality Index
EQ-5D: Euro Quality-of-Life 5-Dimension Health
Status Questionnaire
HRQoL: health-related quality of life
IGA: Investigator’s Global Assessment
IgG: immunoglobulin G
IL: interleukin
PASI: Psoriasis Area and Severity Index
ppIGA: Palmoplantar Investigator’s Global
Assessment
ppPASI: Palmoplantar Psoriasis Area and Severity
Index
ppPGA: Palmoplantar Physician Global
Assessment
ppQLI: Palmoplantar Quality-of-Life Instrument
QoL: quality of life
SAE: serious adverse event
SGA: Subject Global Assessment
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72 Gottlieb et alpustulosis) were excluded. Previous exposure to
secukinumab or other drugs directly targeting IL-17A
or the IL-17 receptor were prohibited. During the
study, no concomitant use of any other psoriasis
treatments was allowed, including topical therapies
such as corticosteroids.Assessments
The primary objective was to demonstrate the
superiority of secukinumab 300 and/or 150 mg
versus placebo based on a ppIGA of 0 or 1 response
and a reduction of at least 2 points on the ppIGA
scale from baseline to week 16. The ppIGA scale was
based on the IGA modified version 2011,25
specifically applied to the palms and soles.
Secondary objectives included the evaluation of
ppIGA and Palmoplantar Psoriasis Area and
Severity Index (ppPASI) over time from baseline to
week 16 comparing treatment groups with placebo.
The ppPASI was based on the PASI26,27 but applied
only to the palms and soles: each palm contributed
20% and each sole contributed 30% to the
total palmoplantar surface area. Subject-reported
outcomes included the Dermatology Life Quality
Index (DLQI),28 Palmoplantar Quality-of-Life
Instrument (ppQLI),29 Subject Global Assessment
(SGA) of disease activity, and EuroQoL
5-Dimension Health Status Questionnaire (EQ-
5D).30,31 The ppQLI assesses relevant dimensions
affected by palmoplantar psoriasis: pain/discomfort,
functionality, and social/activity limitations, and the
SGA assesses subjects’ well-being, considering all the
ways palmoplantar psoriasis affected them, from
very poor (0 mm) to very good (100 mm). Safety
and tolerability were evaluated by adverse events(AE), laboratory and vital sign assessments, and
physical examinations.
Statistical analyses
The ppIGA response was compared between
secukinumab and placebo using Cochran-
Mantel-Haenszel test stratified by body weight.
Nonresponder imputation was used to impute
missing ppIGA data, in which a subject was
considered to be a ppIGA nonresponder regardless
of the reason for missing data. An additional
sensitivity analysis was carried out by using multiple
imputation to predict the most likely value for the
missing ppIGA data, based on known characteristics
of a particular subject and all other subjects in the
study.
RESULTS
Subjects
The distribution of the subjects across the
sites/countries was balanced. Of the 277 subjects
screened, 205 were randomized to one of the three
study groups (Fig 2). Approximately 92% of subjects
completed the 16-week treatment period.
The baseline characteristics were similar between
treatment groups (Table I). All subjects hadmoderate
to severe palmoplantar psoriasis with the majority
(72.2%) having a BSA \10%. More than half
of subjects (58.5%) were previously exposed to
nonbiologic systemic therapies; 10.7%were exposed
to biologics with the majority failing previous
biologic therapy (7.8%).
Efficacy
Both secukinumab doses were superior to
placebo at week 16 with respect to a ppIGA 0/1
response. Overall, 33.3% of subjects on secukinu-
mab 300 mg, 22.1% on secukinumab 150 mg, and
1.5% on placebo (P \ .0001 and P = .0002,
respectively vs placebo) achieved this endpoint
(Fig 3). Both secukinumab doses exhibited
consistently higher percentages of ppIGA 0/1
responders compared to placebo over time to
week 16, starting as early as week 2 for secukinumab
300 mg (Fig 3). Across all measures secukinumab
300 mg showed the greatest efficacy. Similar results
were observed with multiple imputation data at
week 16, with 39.3% of subjects on secukinumab
300 mg, 23.1% on secukinumab 150 mg, and 1.5% on
placebo achieving a ppIGA 0/1 response (P\.0001
and P = .0002, respectively vs placebo) (data not
shown). In subjects receiving secukinumab 300 mg
that had previously failed biologics, ppIGA 0/1
response rate remained similar to the overall
population (33.3%).
Fig 1. Study design. Subjects received secukinumab 300 mg, secukinumab 150 mg, or placebo
every week from baseline to week 3 and then every 4 weeks from week 4 to 16. *Subjects in the
placebo arm who were not ppIGA 0 or 1 responders at week 16 were re-randomized (1:1) to
secukinumab 300 mg or 150 mg. ppIGA responders are subjects who achieved a ppIGA 0 or 1
score and at least a 2-point reduction on the ppIGA scale from baseline; ppIGA nonresponders
are subjects who did not achieve a ppIGA 0 or 1 score and at least a 2-point reduction on the
ppIGA scale from baseline. BL, Baseline; EOTP, end of treatment period; EOF, end of follow-up
period; ppIGA, Palmoplantar Investigator’s Global Assessment; sc, subcutaneous.
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16 was consistently greater with secukinumab
compared with placebo. At week 16, ppPASI
reduction from baseline was significant, with
secukinumab 300 mg (54.5%) and 150 mg
(35.3%) compared with placebo (4.0%;
P\ .0001 and P = .0006, respectively) (Fig 4).
Fig 5 shows photographs of the palms and soles
from subjects at baseline, week 4, and 16.
Subject-reported outcomes
At baseline, skin problems had a very large effect
on subjects’ lives (median DLQI 13-14). At week 16,
the percentage of subjects achieving a DLQI score of
0/1, indicating no impact of skin problems on their
lives, was significantly higher with secukinumab
300 mg (26.6%) and 150 mg (16.9%) comparedwith placebo (1.5%, P \ .0001 and P \ .005,
respectively) (Fig 6).
ppQLI captured more HRQoL information
because it is specific to aspects relevant for
palmoplantar psoriasis. It showed that the
percentage of subjects experiencing no difficulty
due to involvement of both palms and soles
increased from 0% at baseline to 12.5% and 10.8%
at week 16 for secukinumab 300 mg and 150 mg,
respectively, and did not change for placebo
(Fig 7, A). Subjects reporting no difficulty due to
palm (Fig 7,B) or sole (Fig 7,C ) involvement at week
16 are presented separately. At baseline, HRQoL was
overall more impaired due to psoriasis on the palms
than on the soles. As a result of psoriasis of the
palms, 50%-60% of subjects at baseline reported
moderate-to-extreme hand pain, work limitation,
Fig 2. GESTURE subject disposition.
Table I. Patient demographic and baseline disease characteristics
Characteristic
Secukinumab
300 mg (n = 69)
Secukinumab
150 mg (n = 68) Placebo (n = 68)
Age, years, mean 6 SD 48.8 6 14.2 52.4 6 12.6 50.9 6 13.0
Male sex, n (%) 38 (55.1) 40 (58.8) 34 (50.0)
Caucasian, n (%) 67 (97.1) 63 (92.6) 65 (95.6)
Weight, kg mean 6 SD 84.8 6 18.3 84.1 6 18.4 84.4 6 20.0
BMI, kg/m2 mean 6 SD 29.2 6 5.8 28.8 6 5.7 28.8 6 5.7
Current smokers, n (%) 26 (37.7) 26 (38.2) 18 (26.5)
Time since palmoplantar psoriasis diagnosis, years 7.9 6 8.2 7.5 6 8.8 11.8 6 10.4
ppIGA score, n (%)
3 (moderate) 50 (72.5) 39 (57.4) 46 (67.6)
4 (severe) 19 (27.5) 29 (42.6) 22 (32.4)
ppPASI score, mean 6 SD 23.9 6 13.2 24.1 6 15.8 24.1 6 14.4
PASI score, mean 6 SD 8.0 6 9.6 8.7 6 10.4 7.7 6 7.3
BSA score, mean 6 SD; Min-Max 9.76 (15.2; 0.3-66.0) 10.5 6 (15.3; 0.1-81.0) 9.5 6 (12.1; 0.3-68.0)
BSA\10%, n (%) 54 (78.3) 47 (69.1) 47 (69.1)
Previous exposure to nonbiologic systemic therapy,
n (%)
42 (60.9) 36 (52.9) 42 (61.8)
Previous failure of nonbiologic systemic therapy,
n (%)
38 (55.1) 35 (51.4) 35 (51.4)
Previous exposure to biologic therapies, n (%) 5 (7.2) 9 (13.2) 8 (11.8)
Previous failure of biologic therapies, n (%) 3 (4.3) 6 (8.8) 7 (10.3)
1 biologic 0 (0) 1 (1.5) 3 (4.4)
$2 biologics 3 (4.3) 5 (7.3) 4 (5.9)
Previous exposure to anti-psoriatic topicals, n (%) 31 (44.9) 36 (52.9) 24 (35.3)
DLQI, median 14 13 13
Values represent mean 6 SD unless otherwise stated.
BMI, Body mass index; BSA, body surface area; DLQI, Dermatology Life Quality Index; Max, maximum value; Min, minimum value; ppIGA,
Palmoplantar Investigator’s Global Assessment; ppPASI, Palmoplantar Psoriasis Area and Severity Index; SD, standard deviation.
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and less confident. Due to psoriasis of the soles,
almost 50% of subjects reported moderate-to-
extreme pain/inability to walk and work. At
week 16, these percentages were halved with
secukinumab 300 mg. With the SGA, subjects
reported a median improvement in HRQoL aftertreatment for palmoplantar psoriasis: 55.4%, 29.6%,
and 14.0% for secukinumab 300 mg, 150 mg, and
placebo, respectively, at week 16 (Fig 7, D).
EQ-5D also revealed significant health impair-
ment of subjects at baseline, with improvements
being observed with both doses of secukinumab at
week 16 (Fig 8).
Fig 3. ppIGA 0/1 responders over time. The percentage of
subjects with moderate-to-severe palmoplantar psoriasis
who achieved a ppIGA 0/1 and a reduction of at least 2
points from baseline on the ppIGA scale over 16 weeks of
treatment by nonresponder imputation. **P \ .001 vs
placebo; ***P \ .0001 vs placebo. ppIGA, Palmoplantar
Investigator’s Global Assessment.
Fig 4. Percentage change in ppPASI over time. The mean
percentage change from baseline of ppPASI in subjects
with moderate-to-severe palmoplantar psoriasis over
16 weeks by multiple imputation. *P \ .05 vs placebo,
**P \ .001 vs placebo, ***P \ .0001 vs placebo. ppPASI,
Palmoplantar Psoriasis Area and Severity Index.
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All groups had a similar duration of exposure to
the study treatments (Table II). The proportion of
subjects experiencing at least one AE was slightly
higher with secukinumab 300 mg and 150 mg (58.0%
and 64.7%, respectively) than with placebo (50.0%).
The most common AEs across all groups were
headache, nasopharyngitis, and upper respiratory
tract infection. The incidence of serious AEs (SAEs)
was slightly higher with secukinumab 150 mg
compared with secukinumab 300 mg and placebo
(5.9%, 2.9%, and 2.9%, respectively). All SAEs were
nonfatal and single events. No major cardiac events
or opportunistic infections were reported. Rare AEsare not reported according to treatment here to
maintain blinding until the end of the study. Three
cases of nonserious superficial Candida infection
were observed; all were mild to moderate, easily
manageable, treated with appropriate medication,
and did not lead to study treatment discontinuation.DISCUSSION
The study met its primary objective. Both doses of
secukinumab were superior to placebo in ppIGA 0/1
response, with secukinumab 300 mg consistently
showing the highest efficacy. The one-third of
subjects who received secukinumab 300 mg
achieved clear or almost clear palms and soles (or
ppIGA 0/1) at week 16with clear differentiation from
placebo as early as week 2. At week 16, palmoplantar
disease improved on average by 55%, based on
ppPASI. Prior failure with biologic therapies had no
impact on secukinumabs efficacy, although the study
was not statistically powered to compare biologic
failure and non-failure cohorts. The improvement
and dose response seen clinically with secukinumab
also translated into improvements in HRQoL. Over
one quarter of subjects taking secukinumab 300 mg
reported that skin problems had no effect on their
lives at week 16 (DLQI 0/1). HRQoL, as impacted by
palmoplantar psoriasis, improved overall by 55% (as
measured by SGA), and an absence of any difficulty
due to palms and soles at week 16 was reported by
12.5% of subjects on secukinumab 300 mg (by
ppQLI). The number of subjects with moderate-to-
extreme pain and work limitations due to palmo-
plantar psoriasis was halved in the same period.
To date, GESTURE is the only large, randomized,
double-blind, placebo-controlled study to report
results on efficacy and safety in subjects with
palmoplantar psoriasis. This study was specifically
designed for palmoplantar psoriasis; subjects who
did not have extensive plaque psoriasis on areas
other than the palms and soles were also included
(nearly 3 out of 4 subjects had a BSA\10%). Subjects
were, however, required to have at least one
additional plaque on a body part other than the
palms and soles to confirm the psoriasis diagnosis.
We included subjects regardless of previous biologic
therapy or failure to better represent a population
seen in everyday clinical practice. This study is also
the first, to our knowledge, to examine in detail the
impact of palmoplantar psoriasis on HRQoL at
baseline in the absence of confounding therapies.
Unlike prior published research,2,5 we observed
profound HRQoL impairment in palmoplantar
psoriasis at baseline, even with the generic tool
EQ-5D.
Fig 5. Photographs of the palms and soles from the GESTURE study. The images of the palms
are from two different subjects (A and B) and the soles are from 2 different subjects (C and D).
A, Man in his early fifties with a 3-year palmoplantar psoriasis history who had previously failed
several topicals and phototherapy. His ppPASI score was reduced by 66% at week 16. At
baseline he reported moderate difficulty with hand dexterity, burning sensations, and
inability to work, as well as feeling embarrassed and less confident due to hands. He reported
J AM ACAD DERMATOL
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=Fig 6. Percentage of DLQI 0/1 responders at week 16. *P\ .01 vs placebo; ***P\ .0001 vs
placebo. DLQI, Dermatology Life Quality Index.
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difficult and even more so in this patient population
in which results obtained thus far are limited by
small sample size and different/heterogeneous study
populations.12-15 Previously, the strongest evidence
came from a study with adalimumab in moderate-to-
severe palmoplantar psoriasis. In this study, adali-
mumab treatment resulted in 15 of 49 subjects (31%)
achieving clear or almost clear palms and soles
versus 1 of 23 (4%) on placebo.13 However, some
subjects had psoriasis on the backs of their hands
and feet rather than on the palms and soles, and the
study allowed concomitant use of low-to-mid
potency topical corticosteroids. In another smaller,
controlled trial, 3 of 12 (25%) patients on infliximabalmost no difficulty with hand dexterity, reduce
limitation, as well as no longer being embarrassed
sixties with 7-month palmoplantar psoriasis histor
previously failed phototherapy. After 16 weeks,
quarters (by ppPASI). From severe hand pain, bu
impairment, being very limited in work, and feelin
he reported almost no hand dexterity impairment,
on work, and no longer being embarrassed at wee
palmoplantar psoriasis history who had previou
Sole lesions completely cleared at week 16. From
fast/running at baseline, he reported absence of a
twenties with a 1-year palmoplantar psoriasis h
Psoriasis of the soles was improved by 66% (by pp
extreme pain while walking, moderate impact on
doing what she wanted, resulting in her frequently
pain, no difficulty walking, and no impact on
Palmoplantar Psoriasis Area and Severity Index.and 1 of 12 (8.3%) on placebo had clear or almost
clear palms and soles at week 14.12 Ustekinumab in
an open-label, single-center study involving 20
patients showed a 35% Palmoplantar Physician
Global Assessment (ppPGA) 0/1 response at week
16, but the study was not placebo-controlled.14 In
addition to these studies, there are several subgroup/
post-hoc analyses, which are limited by the fact that
palmoplantar psoriasis was not the primary focus of
the trials. In the largest post-hoc analysis of
apremilast, 22 of 57 patients (38.6%) versus 8 of 26
(30.8%) with placebo achieved a ppPGA 0/1
response at week 16.15 This placebo response is
unusually high given the slowly progressing natural
course of palmoplantar psoriasis.d/mild/slight burning of palms and work
and less confident at week 16. B, Man in his
y (overall 44 years of psoriasis history) who
palm psoriasis improved by almost three
rning and itching, moderate hand dexterity
g embarrassed due to his palms at baseline,
mild pain, burning and itching, slight impact
k 16. C, Man in his early sixties with a 10-year
sly failed topical and ciclosporin therapy.
moderate difficulty walking and walking
ny limitations at week 16. D, Woman in her
istory who had previously failed topicals.
PASI) at week 16. From severe difficulty and
work, extreme interference with life and in
staying indoors at baseline. She reported no
her work and life at week 16. ppPASI,
Fig 7. Palmoplantar psoriasisespecific QoL. ppQLI in subjects at baseline and week 16 (A-C).
The percentage of subjects who experienced no difficulty due to palms and soles (A), palms
(B), or soles (C) as assessed using the ppQLI. D, SGA of palmoplantar psoriasis after 16 weeks
of treatment. BL, Baseline; ppQLI, palmoplantar Quality-of-Life Instrument; QoL, quality of life;
SGA, Subject Global Assessment.
J AM ACAD DERMATOL
JANUARY 2017
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difficult-to-treat nature of palmoplantar psoriasis
compared with psoriasis on other locations of the
body where higher rates of efficacy are more readily
achieved. Furthermore, it highlights the need for
more research given the paucity of randomized
controlled studies dedicated to palmoplantar
psoriasis to date. In this context, given the large
sample size, homogeneous target patient popula-
tion, and the prospective, placebo-controlled study
design, GESTURE provides the best evidence for
high efficacy of a therapy in this population, with the
efficacy of secukinumab appearing better than that
seen with other therapies in the initial 16-week
period. Furthermore, GESTURE confirmed the
favorable safety profile of secukinumab,18-22 with
no new safety concerns in subjects with palmoplan-
tar psoriasis.
The study included placebo; however, it is limited
by the absence of an active comparator. The study isongoingwith results up to 132weeks expected in the
future.
GESTURE provides the most robust data in
subjects with palmoplantar psoriasis to date and
significantly contributes to the body of evidence that
may be used to inform treatment decisions and
guidelines for this rarely studied population.
Secukinumab demonstrated significant efficacy in
palmoplantar psoriasis with a favorable safety
profile, thus offering a valuable new treatment op-
tion for plaque psoriasis in difficult-to-treat locations.
The authors would like to thank the subjects who are
participating in the study and the study investigators
across numerous international sites: Australia (J. Sullivan,
L.J. Spelman, R.D. Sinclair, and P.A. Foley), Belgium
(P.D. Ghislain and A.F. Nikkels), Canada (K. Papp, K.
Barber, W.D. Carey, L. Guenther, and R.A. Kunynetz),
Finland (R. Pasternack and T. M€alk€onen), Hungary
(A. Vajda, Z. Karolyi, L. Kemeny, and E. Remenyik),
Israel (R. Tal, M. Ziv, H. Matz, and M. David),
Fig 8. EQ-5D health state assessment at baseline and at week 16. BL, Baseline; EQ-5D, Euro
Quality-of-Life 5-Dimension Health Status Questionnaire.
Table II. Summary of adverse events
Secukinumab 300 mg (n = 69) Secukinumab 150 mg (n = 68) Placebo (n = 68)
Exposure to study treatment, days mean (SD) 109.8 (21.6) 112.7 (9.6) 111.3 (15.3)
Any AEs, n (%) 40 (58.0) 44 (64.7) 34 (50.0)
Death, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Nonfatal SAEs, n (%) 2 (2.9) 4 (5.9) 2 (2.9)
Discontinuations due to AEs, n (%) 2 (2.9) 1 (1.5) 2 (2.9)
Most common AEs, n (%)*
Headache 7 (10.1) 4 (5.9) 6 (8.8)
Nasopharyngitis 2 (2.9) 5 (7.4) 4 (5.9)
Upper respiratory tract infection 3 (4.3) 4 (5.9) 3 (4.4)
AE, Adverse event; SAE, serious adverse event; SD, standard deviation.
*Expressed by preferred term and occurring at an incidence $5% in any secukinumab group. AEs are listed in descending order of
frequency.
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